FGF19 and metabolic dysfunction-associated steatotic liver disease: In MASLD, this regulatory pathway becomes compromised, with observed hepatic CYP7A1 overexpression and diminished circulating FGF19 levels reflecting disruption of the canonical FXR-FGF19-CYP7A1 feedback mechanism[35,41,42].